308 related articles for article (PubMed ID: 31117296)
1. Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis-Learning from Other Diseases.
Mention K; Santos L; Harrison PT
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31117296
[TBL] [Abstract][Full Text] [Related]
2. Rewriting CFTR to cure cystic fibrosis.
Maule G; Ensinck M; Bulcaen M; Carlon MS
Prog Mol Biol Transl Sci; 2021; 182():185-224. PubMed ID: 34175042
[TBL] [Abstract][Full Text] [Related]
3. Genome Editing for Cystic Fibrosis.
Wang G
Cells; 2023 Jun; 12(12):. PubMed ID: 37371025
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
[TBL] [Abstract][Full Text] [Related]
5. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.
King NE; Suzuki S; Barillà C; Hawkins FJ; Randell SH; Reynolds SD; Stripp BR; Davis BR
Hum Gene Ther; 2020 Sep; 31(17-18):956-972. PubMed ID: 32741223
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
Fajac I; Sermet-Gaudelus I
Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
[TBL] [Abstract][Full Text] [Related]
7.
Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
[TBL] [Abstract][Full Text] [Related]
8. Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor.
Amistadi S; Maule G; Ciciani M; Ensinck MM; De Keersmaecker L; Ramalho AS; Guidone D; Buccirossi M; Galietta LJV; Carlon MS; Cereseto A
Mol Ther; 2023 Jun; 31(6):1647-1660. PubMed ID: 36895161
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing.
Maule G; Arosio D; Cereseto A
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486152
[TBL] [Abstract][Full Text] [Related]
11. Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells.
Bulcaen M; Kortleven P; Liu RB; Maule G; Dreano E; Kelly M; Ensinck MM; Thierie S; Smits M; Ciciani M; Hatton A; Chevalier B; Ramalho AS; Casadevall I Solvas X; Debyser Z; Vermeulen F; Gijsbers R; Sermet-Gaudelus I; Cereseto A; Carlon MS
Cell Rep Med; 2024 May; 5(5):101544. PubMed ID: 38697102
[TBL] [Abstract][Full Text] [Related]
12. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
13. A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene.
Fan Z; Perisse IV; Cotton CU; Regouski M; Meng Q; Domb C; Van Wettere AJ; Wang Z; Harris A; White KL; Polejaeva IA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282831
[TBL] [Abstract][Full Text] [Related]
14. Emerging gene therapies for cystic fibrosis.
Miah KM; Hyde SC; Gill DR
Expert Rev Respir Med; 2019 Aug; 13(8):709-725. PubMed ID: 31215818
[No Abstract] [Full Text] [Related]
15. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
Schneider-Futschik EK
Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
[TBL] [Abstract][Full Text] [Related]
16. Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis.
Villate-Beitia I; Zarate J; Puras G; Pedraz JL
Drug Dev Ind Pharm; 2017 Jul; 43(7):1071-1081. PubMed ID: 28270008
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
Fajac I; Sermet I
Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
[TBL] [Abstract][Full Text] [Related]
18. P.F508del editing in cells from cystic fibrosis patients.
Smirnikhina SA; Kondrateva EV; Adilgereeva EP; Anuchina AA; Zaynitdinova MI; Slesarenko YS; Ershova AS; Ustinov KD; Yasinovsky MI; Amelina EL; Voronina ES; Yakushina VD; Tabakov VY; Lavrov AV
PLoS One; 2020; 15(11):e0242094. PubMed ID: 33175893
[TBL] [Abstract][Full Text] [Related]
19. Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction.
Suzuki S; Crane AM; Anirudhan V; Barillà C; Matthias N; Randell SH; Rab A; Sorscher EJ; Kerschner JL; Yin S; Harris A; Mendel M; Kim K; Zhang L; Conway A; Davis BR
Mol Ther; 2020 Jul; 28(7):1684-1695. PubMed ID: 32402246
[TBL] [Abstract][Full Text] [Related]
20. Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.
Maule G; Casini A; Montagna C; Ramalho AS; De Boeck K; Debyser Z; Carlon MS; Petris G; Cereseto A
Nat Commun; 2019 Aug; 10(1):3556. PubMed ID: 31391465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
